新景智源完成B轮融资，加速实体瘤TCR-T细胞治疗药物开发

Recently, Neowise Biotechnology, Co., Ltd. (hereinafter referred to as "Neowise Biotechnology" or "the Company") has completed its Series B financing. This round of financing was jointly invested by Yuanhe Holding, Suzhou Angel Mother Fund, and Tonggao Capital.

Neowise Biotechnology, founded in 2020, is an innovative biotechnology company focused on the research and development of TCR-T immunocyte therapeutic drugs for solid tumors, committed to overcoming the core bottleneck currently faced by cell therapies in the field of solid tumors.

TCR-T Cell Therapy as a Key Branch of Adoptive Cell Therapy Has Garnered Significant Global Attention in Recent Years. Compared to Traditional Chemotherapy or Immune Checkpoint Inhibitors like PD-1, TCR-T Demonstrates the Ability to Specifically Recognize Intracellular Antigens of Tumor Cells, Showing Remarkable Disease Remission Rates and Survival Benefits in the Treatment of Advanced Solid Tumors. However, a Critical Challenge in This Field Remains: How to Efficiently and Safely Screen for Natural High-Affinity TCR Sequences from a Vast Pool of T Cells That Can Precisely Identify Tumor Neoantigens.

Addressing this industry pain point, Neowise Biotechnology has independently developed the world's leading "High-Throughput, High-Sensitivity Target Antigen-Natural TCR Discovery and Validation Platform." This platform innovatively integrates bioinformatics prediction with experimental validation, using a closed-loop feedback mechanism between computational and wet-lab experiments to enable the rapid capture and functional confirmation of extremely low-frequency natural TCRs. Currently, the company has built the world’s largest experimentally validated database of target antigen-natural TCR pairs, covering thousands of high-quality data entries, significantly broadening the pool of eligible patients for TCR-T therapy.

Relying on a robust technology platform, Neowise Biotechnology has successfully advanced multiple TCR-T candidate drugs into clinical trial stages. In clinical studies targeting various solid tumors, the company's products have demonstrated encouraging efficacy and favorable safety profiles. Notably, the TCR sequences screened by its platform exhibit superior performance across multiple dimensions—such as affinity, tumor-killing activity, and off-target risk control—outperforming similar products from leading international pharmaceutical companies.

Currently, the global cell therapy is making in-depth breakthroughs from hematological tumors to solid tumors, and TCR-T is considered one of the key paths to conquering solid tumors. With its first-mover technical advantages and solid clinical advancement capabilities, Neowise Biotechnology has already occupied an important position in this field. The completion of this Series B round of financing marks the capital market's high recognition of the company’s technical barriers, product potential, and team execution.

E.N.D

ForPromote Cooperation and Technical Exchange in the Cell and Gene Therapy IndustryThe team of the WeChat Official Account "Cell and Gene Therapy Field" has established a professional communication group for cell and gene therapy. Press and hold the QR code below to add the editor's WeChat and join the group. Due to the large number of applicants, please include the following when adding WeChat: Institution/Enterprise—Major/Position—Name. If you are a PI/Professor/Manager or above, please also specify.